Intellia Therapeutics — Third Quarter 2026 Earnings Summary

Intellia Therapeutics announced that the FDA accepted its Biologics License Application for lonvo-z, a one-time in vivo CRISPR therapy for hereditary angioedema, granting it Priority Review with a target action date of March 10, 2027. The company completed enrollment in its MAGNITUDE-2 Phase 3 trial for ATTRv-PN and advanced enrollment in the MAGNITUDE trial for ATTR-CM, while securing a $400 million term loan facility to support operations through 2028. For the third quarter of 2026, Intellia reported collaboration revenue of $7.2 million, R&D expenses of $83.3 million, and a net loss of $127.5 million, maintaining a cash position of $614.8 million.